2-Methyl-3-buten-2-ol (Methylbutenol)

In rodent sedation models, intraperitoneal administration of 2M3B2O (120–600 mg/kg) produced dose-dependent reduction in spontaneous locomotor activity, prolonged barbiturate-induced sleep time, and reduced ketamine-induced anesthesia latency — all indicators of GABAergic sedative activity (Wohlfart et al., 1983; Chadha et al., 2002). Human studies isolating 2M3B2O from whole hop preparations are absent; the clinical contribution of this compound relative to other sedative fractions (linalool, humulone, whole-hop terpenes) is inferred from animal pharmacology. Hop preparation age and storage temperature significantly affect 2M3B2O content, which has important implications for product quality standardization.

Animal studies demonstrate dose-dependent CNS depression, hypnosis, and reduced locomotor activity with methylbutenol administration. The compound has been detected in blood following consumption of hop-containing beverages. Human pharmacokinetic data is limited but consistent with significant bioavailability. The clinical significance of methylbutenol vs. other hops constituents to the observed sedative effects in human trials remains partially unresolved.